Citius Pharmaceuticals

Yahoo Finance • last year

Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc.

Citius Pharmaceuticals, Inc. to receive $675 million in equity of Citius Oncology, Inc. and retain approximately 90% majority control in publicly listed Citius Oncology, Inc. post transaction Transaction anticipated to close in the first... Full story

Yahoo Finance • last year

Citius Pharmaceuticals Announces Positive Results from the Phase 2b Study of Halo-Lido (CITI-002) for the Treatment of Hemorrhoids

CITI-002 provides a meaningful reduction in symptom severity when compared to individual components alone Dose for Phase 3 trial selected; Citius to schedule end of Phase 2 meeting with the FDA Trial validates Patient Reported Outcome (P... Full story

Yahoo Finance • 2 years ago

Citius Pharmaceuticals Advances Mino-Lok® Phase 3 Trial Achieving 85 of 92 Events to Date

CRANFORD, N.J., April 24, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical ca... Full story

Yahoo Finance • 2 years ago

Sidoti's January Micro-Cap Conference

NEW YORK, NY / ACCESSWIRE / January 17, 2023 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day January Micro-Cap Conference taking place Wednesday and Thursday, January 18-19, 2023. The links can a... Full story

Yahoo Finance • 3 years ago

10 Penny Stocks to Buy in May

In this article, we will look at 10 penny stocks to buy in May. If you want to explore similar stocks that have the potential to explode in the future, you can also take a look at 5 Penny Stocks to Buy in May. Predicting the future might... Full story

Yahoo Finance • 3 years ago

Shares of Citius jump 18% on new data for experimental lymphoma drug

Shares of Citius Pharmaceuticals Inc. were up 18.5% in premarket trading on Wednesday after the company shared positive topline data from a Phase 3 clinical trial for its experimental treatment for cutaneous T-cell lymphoma, which is a typ... Full story